Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Perspective TherapeuticsAbbVie
Last price
$2.57$265.76
Currency
USD
USD
$293M$470B
-75.08
-$1.25$3.54
1.800.28
0$6.83
02.60%
Sector
HealthHealth
Employees
16557,000
Ticker
$CATX$ABBV
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $CATX or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.